Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.brainres.2017.10.016PMID 29066367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia

  2018cited by this paper
• Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

  2017cited by this paper
• Defining imaging biomarker cut points for brain aging and Alzheimer's disease

  2017cited by this paper
• Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline

  2017cited by this paper
• A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

  2017cited by this paper
• Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design

  2017cited by this paper
• Association between tau deposition and antecedent amyloid-&bgr; accumulation rates in normal and early symptomatic individuals

  2017cited by this paper
• Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease

  2016cited by this paper
• Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease

  2016cited by this paper
• Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

  2016cited by this paper
• Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

  2016cited by this paper
• Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnestic Presentation: CSF and 18F-FDG PET Study

  2016cited by this paper
• The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

  2016cited by this paper
• Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

  2016cited by this paper
• PET Imaging of Tau Deposition in the Aging Human Brain.

  2016cited by this paper
• Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

  2016cited by this paper
• The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function

  2015cited by this paper
• Alzheimer’s Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy

  2015cited by this paper
• Cortical activity during olfactory stimulation in multiple chemical sensitivity: a 18F-FDG PET/CT study

  2015cited by this paper
• Functional correlates of t-Tau, p-Tau and A&bgr;1–42 amyloid cerebrospinal fluid levels in Alzheimer’s disease: a 18F-FDG PET/CT study

  2015cited by this paper
• Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity

  2015cited by this paper
• FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

  2014cited by this paper
• Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Primary age-related tauopathy (PART): a common pathology associated with human aging

  2014cited by this paper
• Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study

  2014cited by this paper
• Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

  2014cited by this paper
• Cerebellar metabolic involvement and its correlations with clinical parameters in vestibular neuritis

  2014cited by this paper
• Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

  2012cited by this paper
• Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With A&bgr; Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue

  2012cited by this paper
• Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?

  2010cited by this paper
• Interhemispheric Distribution of Alzheimer Disease and Vascular Pathology in Brain Aging

  2009cited by this paper
• Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

  2009cited by this paper
• Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

  2009cited by this paper
• Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

  2009cited by this paper
• CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.

  2008cited by this paper
• CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease

  2008cited by this paper
• No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease.

  2007cited by this paper
• Clinical and empirical applications of the Rey–Osterrieth Complex Figure Test

  2006cited by this paper
• Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia.

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Rey-Osterrieth complex figure: normative values in an Italian population sample

  2002cited by this paper
• Statistical Parametric Mapping of 99mTc-HMPAO-SPECT Images for the Diagnosis of Alzheimer's Disease: Normalizing to Cerebellar Tracer Uptake

  2002cited by this paper
• Age Differences in the Frontal Lateralization of Verbal and Spatial Working Memory Revealed by PET

  2000cited by this paper
• The CA1 Region of the Human Hippocampus Is a Hot Spot in Alzheimer's Disease

  2000cited by this paper
• Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward‐transform method

  1997cited by this paper
• The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery.

  1996cited by this paper
• The Mini-Mental State Examination in Alzheimer's Disease and Multi-Infarct Dementia

  1996cited by this paper

• Energetic implications of fMRI-based nodal complex network metrics: a complex picture unfolds across diverse brain states

  2026cites this paper
• Live Effects of Anodal and Cathodal Transcranial Direct Current Stimulation on Brain Metabolism in a Patient with Typical Hemorrhagic Stroke: A Case Study

  2025cites this paper
• The usefulness of combined analysis using CIScore and VSRAD parameters for differentiating between dementia with Lewy body and Alzheimer’s disease

  2024cites this paper
• Relationship between neuroimaging and emotion recognition in Mild Cognitive Impairment patients.

  2024cites this paper
• Regional brain metabolism across the Alzheimer's Disease continuum in Down Syndrome

  2024influential citation
• Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise

  2023cites this paper
• Traumatic brain injury and the pathways to cerebral tau accumulation

  2023cites this paper
• Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

  2023cites this paper
• Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer’s disease: an exploratory study of ^18F-FDG-PET

  2023cites this paper
• Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer’s Disease: A CSF/18F-FDG-PET Study

  2023cites this paper
• Brain 18F‐FDG‐PET and an optimized cingulate island ratio to differentiate Lewy body dementia and Alzheimer's disease

  2022cites this paper
• The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia

  2022cites this paper
• Correlation of [18F]florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach

  2021cites this paper
• Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

  2021cites this paper
• Impairments in Brain Bioenergetics in Aging and Tau Pathology: A Chicken and Egg Situation?

  2021cites this paper
• Tau-PET imaging as a molecular modality for Alzheimer's disease.

  2021cites this paper
• Plasma tau predicts cerebral vulnerability in aging

  2020cites this paper
• Psychiatric Disorders in Dementia

  2020cites this paper
• The role of epsilon phenotype in brain glucose consumption in Alzheimer’s disease

  2020cites this paper
• The Brain Metabolic Correlates of the Main Indices of Neuropsychological Assessment in Alzheimer’s Disease †

  2020cites this paper
• PET/CT and PET/MRI, Normal Variations, and Artifacts

  2020cites this paper
• Cortical metabolic changes and clinical outcome in normal pressure hydrocephalus after ventriculoperitoneal shunt: Our preliminary results.

  2020cites this paper
• From beta amyloid to altered proteostasis in Alzheimer's disease.

  2020cites this paper
• The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore

  2020cites this paper
• Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes

  2020cites this paper
• Amelioration of oxidative stress and neuroinflammation in lipopolysaccharide-induced memory impairment using Rosmarinic acid in mice

  2020cites this paper
• Cambios metabólicos corticales y resultado clínico en la hidrocefalia normotensiva después de la derivación ventrículo-peritoneal: nuestros resultados preliminares

  2020cites this paper
• Cortical metabolic changes and clinical outcome in normal pressure hydrocephalus after ventriculoperitoneal shunt: our preliminary results

  2020cites this paper
• Biomarkers for tau pathology

  2019cites this paper
• Advances and considerations in AD tau-targeted immunotherapy

  2019cites this paper
• Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?

  2019cites this paper
• Coupled Imaging with [18F]FBB and [18F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical Dysfunction in the Brain

  2018cites this paper
• Nuclear medicine and anatomic pathology in personalized medicine: a challenging alliance.

  2018cites this paper
• The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer’s disease

  2018cites this paper
• Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer’s Disease

  2018cites this paper